Stocks

Headlines

Almirall Reports Profit and Revenue Growth in Fiscal 2024

Almirall S.A. transitions to profitability in fiscal 2024, as it reports net income of 10.1 million euros versus a loss last year. With expected 10-13% net sales growth for fiscal 2025, the outlook appears positive.

Date: 
AI Rating:   7
Financial Highlights: Almirall, S.A. has achieved notable financial improvements in fiscal 2024, including a shift from a net loss to a net income of 10.1 million euros, indicating strong operational recovery. In terms of Net Income, the reported 10.1 million euros represents a significant recovery from the previous year's loss of 38.5 million euros. This turnaround suggests improved profitability and may boost investor confidence in the company's future performance. The company's Total EBITDA also showed a robust increase, up 10.6 percent to 192.6 million euros from 174.1 million euros last year. This exceeds the company's own guidance, reflecting better-than-expected operational efficiency and possibly lower costs or higher sales prices. Regarding Revenue Growth, Almirall saw a 10.2 percent increase in total revenues, totaling 990.6 million euros compared to 898.8 million euros in the previous year. This performance not only meets expectations but indicates strong sales driven primarily by the European Dermatology market and its biologics segment. Looking ahead, Almirall maintains a positive outlook for fiscal 2025, projecting a net sales growth of 10 to 13 percent and an EBITDA range of 220 million to 240 million euros. These projections signal continued growth and investment potential for investors interested in biopharmaceuticals.
Stocks:  LBTSF.PK